<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04461535</url>
  </required_header>
  <id_info>
    <org_study_id>ADOPA study</org_study_id>
    <nct_id>NCT04461535</nct_id>
  </id_info>
  <brief_title>Compare Outcomes of AVS With or Without ACTH Stimulation</brief_title>
  <official_title>Adrenal Venous Sampling With or Without Adrenocorticotropic Hormone Stimulation to Determine Outcomes in Primary Aldosteronism: an Outcome-based Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of different procedures of AVS(with or without ACTH stimulation) on the
      long-term outcomes of patients with APA
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, single-center study study involving 200 patients with
      primary aldosteronism(PA) who are willing to undergo surgery.

      All paticipants will be randomly divided into ACTH-stimulated group(Intervention group,n=70)
      and ACTH-unstimulated group(Control group,n=70) and to compare the long-term outcomes of
      patients with PA, in whom the lateralization of aldosterone hypersecretion was according to
      different procedures of AVS(with or without ACTH stimulation).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the rate of complete biochemical remission between two groups</measure>
    <time_frame>At 12 months of follow-up.</time_frame>
    <description>Blood was drawn to measure aldosterone, renin and potassium.According to PASO criteria, outcomes of adrenalectomy for unilateral primary aldosteronism were classified into complete, partial, and absent success, for both clinical and biochemical outcomes.The proportion of complete biochemical remission according to PASO consensus criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete clinical remission</measure>
    <time_frame>At 12 months of follow-up.</time_frame>
    <description>The proportion of complete clinical remission according to PASO consensus criteria.Clinical outcomes were determined by the blood pressure response to treatment and the number and dosage of antihypertensive medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily defined doses (DDD) of antihypertensive agents</measure>
    <time_frame>At 12 months of follow-up.</time_frame>
    <description>When patients' blood pressure get well controlled(SBP&lt;140mmHg and DBP&lt;90mmHg), calculate the daily defined doses (DDD) of antihypertensive agents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful catheterization.</measure>
    <time_frame>At baseline</time_frame>
    <description>Calculate the rate of successful catheterization.Successful catheterization was defined as SI≥2 without ACTH stimulation or SI≥3 with ACTH stimulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>At baseline and 1 month of follow-up.</time_frame>
    <description>Record the occurrence of adverse events, including adrenal venous hemorrhage and related adrenal insufficiency, hypertensive urgencies, anaphylactic shock, venous thrombosis, pulmonary embolism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The health-related quality of life</measure>
    <time_frame>At baseline and 12 months of follow-up.</time_frame>
    <description>Compare the quality of life score between two groups,using EuroQol-5 Dimension Visual Analogue Scale (VAS) score.The minimum and maximum values are 0 and 100,respectively. And higher scores mean a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Primary Aldosteronism</condition>
  <arm_group>
    <arm_group_label>AVS with ACTH stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients divided into AVS with ACTH stimulation group need to undergo stimulation with a continuous cosyntropin infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVS without ACTH stimulation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients divided into AVS without ACTH stimulation group take the same procedure of AVS except for continuous cosyntropin infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cosyntropin</intervention_name>
    <description>Patients divided into Intervention group need to undergo stimulation with a continuous cosyntropin infusion (50 μg/h started 30 minutes before sampling during AVS). Right and left adrenal venous blood and corresponding peripheral venous blood should be sampled sequentially.</description>
    <arm_group_label>AVS with ACTH stimulation</arm_group_label>
    <other_name>ACTH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Understand the whole process of the trial and voluntarily accept randomized grouping,
             intervention and follow-up;

          2. Voluntarily participate in the study and sign the informed consent form, willing to
             complete all follow-ups as required;

          3. Age 18 or above, male or female, with legal capacity;

          4. Hypertension patients with positive PA screening (ARR&gt;20) and at least two positive PA
             diagnostic tests (CCT, SIT or FST);

        Exclusion Criteria:

        Patients with one of the following conditions cannot be included in this study:

          1. Pregnant or lactating women

          2. Patients with a history of malignant tumors

          3. Having contraindications or refusal to undergo AVS or unilateral adrenalectomy, or
             allergy to ACTH;

          4. PA combined with Cushing syndrome (including subclinical Cushing);

          5. Considering glucocorticoid-suppressible aldosteronism (GRA) or adrenocortical
             carcinoma;

          6. Drugs which have a relevant effect on the treatment prescribed in this study are
             currently used and cannot be stopped or changed, or it may cause high blood pressure
             and hypertension, such as glucocorticoids.

          7. Complicated with severe heart disease (including pacemaker implantation), severe
             cardiac dysfunction, severe anemia (Hb&lt;60g/L), stroke or acute coronary syndrome
             within 3 months, severe ascites and liver cirrhosis at baseline, etc., which can
             seriously interfere with subsequent treatment of PA or health-related quality of life
             assessment.

          8. Alcoholics, drug users, and mentally disabled patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qifu Li, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>the Chongqing Primary Aldosteronism Study (CONPASS) Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qifu Li, PhD</last_name>
    <phone>+86 023-89011552</phone>
    <email>liqifu@yeah.net</email>
  </overall_contact>
  <results_reference>
    <citation>Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916. doi: 10.1210/jc.2015-4061. Epub 2016 Mar 2.</citation>
    <PMID>26934393</PMID>
  </results_reference>
  <results_reference>
    <citation>Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, Tanabe A; Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society. Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. Endocr J. 2011;58(9):711-21. Epub 2011 Aug 9.</citation>
    <PMID>21828936</PMID>
  </results_reference>
  <results_reference>
    <citation>Deinum J, Groenewoud H, van der Wilt GJ, Lenzini L, Rossi GP. Adrenal venous sampling: cosyntropin stimulation or not? Eur J Endocrinol. 2019 Sep;181(3):D15-D26. doi: 10.1530/EJE-18-0844. Review.</citation>
    <PMID>31176302</PMID>
  </results_reference>
  <results_reference>
    <citation>Buffolo F, Monticone S, Williams TA, Rossato D, Burrello J, Tetti M, Veglio F, Mulatero P. Subtype Diagnosis of Primary Aldosteronism: Is Adrenal Vein Sampling Always Necessary? Int J Mol Sci. 2017 Apr 17;18(4). pii: E848. doi: 10.3390/ijms18040848. Review.</citation>
    <PMID>28420172</PMID>
  </results_reference>
  <results_reference>
    <citation>Dekkers T, Prejbisz A, Kool LJS, Groenewoud HJMM, Velema M, Spiering W, Kołodziejczyk-Kruk S, Arntz M, Kądziela J, Langenhuijsen JF, Kerstens MN, van den Meiracker AH, van den Born BJ, Sweep FCGJ, Hermus ARMM, Januszewicz A, Ligthart-Naber AF, Makai P, van der Wilt GJ, Lenders JWM, Deinum J; SPARTACUS Investigators. Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial. Lancet Diabetes Endocrinol. 2016 Sep;4(9):739-746. doi: 10.1016/S2213-8587(16)30100-0. Epub 2016 Jun 17.</citation>
    <PMID>27325147</PMID>
  </results_reference>
  <results_reference>
    <citation>Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, Satoh F, Amar L, Quinkler M, Deinum J, Beuschlein F, Kitamoto KK, Pham U, Morimoto R, Umakoshi H, Prejbisz A, Kocjan T, Naruse M, Stowasser M, Nishikawa T, Young WF Jr, Gomez-Sanchez CE, Funder JW, Reincke M; Primary Aldosteronism Surgery Outcome (PASO) investigators. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017 Sep;5(9):689-699. doi: 10.1016/S2213-8587(17)30135-3. Epub 2017 May 30.</citation>
    <PMID>28576687</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Qifu Li</investigator_full_name>
    <investigator_title>Professor.Qifu Li</investigator_title>
  </responsible_party>
  <keyword>primary aldosteronism</keyword>
  <keyword>adrenal venous sampling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cosyntropin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

